EMBC
What one share of Embecta holds
Surgical and Medical Instruments and Apparatus
Building on our 100-year centennial, we believe that our products have become one of the most widely recognized and respected brands in diabetes management throughout the world. We estimate that our products are used by more than 30 million people in over 100 countries for insulin administration and to aid with the daily management of diabetes.
Embecta’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $17.10 |
|---|---|
| Profit | $1.47 |
| Capex (buildings and equipment) | $0.16 |
| Free cash flow | $2.76 |
| Dividends | $0.46 |
| Cash and investments | $3.79 |
| Debt | $26.23 |
| Book value | −$10.81 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $19.04 | $7.50 | $0.73 | $8.01 | — | $10.04 |
| 2021 | $20.44 | $7.28 | $0.65 | $7.36 | — | $10.42 |
| 2022 | $19.66 | $3.89 | $0.41 | $6.76 | $0.15 | −$15.62 |
| 2023 | $19.41 | $1.22 | $0.46 | $0.71 | $0.60 | −$14.33 |
| 2024 | $19.26 | $1.34 | $0.27 | $0.34 | $0.60 | −$12.79 |
| 2025 | $18.34 | $1.62 | $0.16 | $3.10 | $0.60 | −$11.12 |